Proteins

After pioneering the microarray technology used to publish more than 20,000 scientific papers, Affymetrix is evolving into a provider of scalable, innovative genomic analysis tools and reagents for discovery, exploration, validation, and genetic testing. The acquisitions of Panomics and USB bring high-throughput, multi- to single-gene assays and premium-value molecular biology reagents to our customers, enabling a complete solution for genome-wide analysis studies and a range of products for cellular and protein analysis studies.

Germinated from assets acquired in 2003 from GSK, Affinium's antibacterial programs now include a broad base of intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors, genes, proteins, assays, crystal structures and combinations of FabInhibitors with known antibiotics. These assets represent a new class of antibiotics with a unique mechanism of action, targeting an unexploited pathway, bacterial fatty acid biosynthesis.